Progress of chimeric antigen receptor T-cell therapy for drug resistance and relapse of hematologic malignancies

VernacularTitle:恶性血液肿瘤嵌合抗原受体T细胞治疗后耐药与复发研究进展
Author: Lu TANG ¹ ; Fen ZHOU ; Heng MEI
Author Information

1. 华中科技大学同济医学院附属协和医院血液科，武汉　430022
Keywords: Hematologic neoplasms; Chimeric antigen receptor T-cell; Drug resistance; Recurrence
From: Journal of Leukemia & Lymphoma 2022;31(4):193-196
CountryChina
Language:Chinese
Abstract: Chimeric antigen receptor T-cell (CAR-T) has made a breakthrough in the treatment of hematologic malignancies, but drug resistance and recurrence have limited its wide application. And at the 63rd annual meeting of the American Society of Hematology, a series of related reports on the mechanism and prevention strategies of drug resistance and recurrence after CAR-T therapy were carried out. These reports provide important indications for improving the clinical efficacy of CAR-T therapy and reducing relapse.